ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: However, it was not until the advent of tyrosine kinase inhibitors (TKIs) targeting the ATP binding site of BCR/ABL in 2001 that significant progress was achieved in CML treatment [6].